|
US9233131B2
(en)
|
2003-06-30 |
2016-01-12 |
The Regents Of The University Of California |
Mutant adeno-associated virus virions and methods of use thereof
|
|
US9441244B2
(en)
|
2003-06-30 |
2016-09-13 |
The Regents Of The University Of California |
Mutant adeno-associated virus virions and methods of use thereof
|
|
US8663624B2
(en)
|
2010-10-06 |
2014-03-04 |
The Regents Of The University Of California |
Adeno-associated virus virions with variant capsid and methods of use thereof
|
|
DK4005603T3
(da)
|
2011-04-22 |
2024-11-25 |
Univ California |
Adeno-associerede virus-virioner med variant kapsid og fremgangsmåder til anvendelse heraf
|
|
TWI702955B
(zh)
|
2012-05-15 |
2020-09-01 |
澳大利亞商艾佛蘭屈澳洲私營有限公司 |
使用腺相關病毒（ａａｖ）ｓｆｌｔ-１治療老年性黃斑部退化（ａｍｄ）
|
|
WO2014093701A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
|
|
EP3434776A1
(en)
|
2012-12-12 |
2019-01-30 |
The Broad Institute, Inc. |
Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
|
|
WO2014093622A2
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
|
|
US10266845B2
(en)
|
2013-02-08 |
2019-04-23 |
The Trustees Of The University Of Pennsylvania |
Enhanced AAV-mediated gene transfer for retinal therapies
|
|
US9567376B2
(en)
|
2013-02-08 |
2017-02-14 |
The Trustees Of The University Of Pennsylvania |
Enhanced AAV-mediated gene transfer for retinal therapies
|
|
SG10201707319UA
(en)
|
2013-03-15 |
2017-10-30 |
Univ Pennsylvania |
Compositions and methods for treating mpsi
|
|
CN112779255A
(zh)
|
2013-05-16 |
2021-05-11 |
应用遗传科技公司 |
用于治疗色盲和其它疾病的启动子、表达盒、载体、药盒和方法
|
|
CA2907799A1
(en)
|
2013-05-31 |
2014-12-04 |
The Regents Of The University Of California |
Adeno-associated virus variants and methods of use thereof
|
|
EP3674411A1
(en)
|
2013-06-17 |
2020-07-01 |
The Broad Institute, Inc. |
Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
|
|
KR20240172759A
(ko)
|
2013-06-17 |
2024-12-10 |
더 브로드 인스티튜트, 인코퍼레이티드 |
간의 표적화 및 치료를 위한 ＣＲＩＳＰＲＣａｓ 시스템, 벡터 및 조성물의 전달 및 용도
|
|
EP3597755A1
(en)
|
2013-06-17 |
2020-01-22 |
The Broad Institute, Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components
|
|
EP3011033B1
(en)
|
2013-06-17 |
2020-02-19 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
|
|
CA2915837A1
(en)
|
2013-06-17 |
2014-12-24 |
The Broad Institute, Inc. |
Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation
|
|
EP3013946B8
(en)
*
|
2013-06-28 |
2019-04-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for expressing a polynucleotide of interest in the retina of a subject
|
|
WO2015004133A1
(en)
|
2013-07-08 |
2015-01-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for performing antisense oligonucleotide-mediated exon skipping in the retina of a subject in need thereof
|
|
US9585971B2
(en)
|
2013-09-13 |
2017-03-07 |
California Institute Of Technology |
Recombinant AAV capsid protein
|
|
EP3080271B1
(en)
|
2013-12-12 |
2020-02-12 |
The Broad Institute, Inc. |
Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
|
|
WO2015089354A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders
|
|
CN105899658B
(zh)
|
2013-12-12 |
2020-02-18 |
布罗德研究所有限公司 |
针对hbv和病毒性疾病以及障碍的crispr-cas系统和组合物的递送、用途和治疗应用
|
|
EP3653229A1
(en)
*
|
2013-12-12 |
2020-05-20 |
The Broad Institute, Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for genome editing
|
|
WO2015089364A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Crystal structure of a crispr-cas system, and uses thereof
|
|
EP3080259B1
(en)
|
2013-12-12 |
2023-02-01 |
The Broad Institute, Inc. |
Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
|
|
GB201403684D0
(en)
*
|
2014-03-03 |
2014-04-16 |
King S College London |
Vector
|
|
WO2015126972A1
(en)
*
|
2014-02-21 |
2015-08-27 |
University Of Florida Research Foundation, Inc. |
Methods and compositions for gene delivery to on bipolar cells
|
|
US10308957B2
(en)
|
2014-03-04 |
2019-06-04 |
University Of Florida Research Foundation, Inc. |
rAAV vectors and methods for transduction of photoreceptors and RPE cells
|
|
EP3957735A1
(en)
|
2014-03-05 |
2022-02-23 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa
|
|
US11339437B2
(en)
|
2014-03-10 |
2022-05-24 |
Editas Medicine, Inc. |
Compositions and methods for treating CEP290-associated disease
|
|
US11141493B2
(en)
|
2014-03-10 |
2021-10-12 |
Editas Medicine, Inc. |
Compositions and methods for treating CEP290-associated disease
|
|
ES2745769T3
(es)
|
2014-03-10 |
2020-03-03 |
Editas Medicine Inc |
Procedimientos y composiciones relacionados con CRISPR/CAS para tratar la amaurosis congénita de Leber 10 (LCA10)
|
|
US10307492B2
(en)
*
|
2014-03-11 |
2019-06-04 |
Wayne State University |
Modified MGLUR6 promoter and methods of use
|
|
ES3042252T3
(en)
|
2014-03-17 |
2025-11-19 |
Adverum Biotechnologies Inc |
Compositions and methods for enhanced gene expression in cone cells
|
|
WO2015148863A2
(en)
|
2014-03-26 |
2015-10-01 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating sickle cell disease
|
|
US12460231B2
(en)
|
2014-04-02 |
2025-11-04 |
Editas Medicine, Inc. |
Crispr/CAS-related methods and compositions for treating primary open angle glaucoma
|
|
WO2015168666A2
(en)
|
2014-05-02 |
2015-11-05 |
Genzyme Corporation |
Aav vectors for retinal and cns gene therapy
|
|
WO2015191508A1
(en)
|
2014-06-09 |
2015-12-17 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
|
KR20170036085A
(ko)
*
|
2014-07-31 |
2017-03-31 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 오클라호마 |
포유동물 rpe65의 높은 아소머로하이드롤라아제 활성 돌연변이
|
|
IL251178B
(en)
*
|
2014-09-16 |
2022-07-01 |
Genzyme Corp |
Adeno-associated viral vector for the treatment of glaucoma myocilin (myoc)
|
|
CN112553229A
(zh)
|
2014-11-05 |
2021-03-26 |
沃雅戈治疗公司 |
用于治疗帕金森病的aadc多核苷酸
|
|
MX2017006217A
(es)
|
2014-11-14 |
2018-05-02 |
Voyager Therapeutics Inc |
Polinucleotidos moduladores.
|
|
RU2020108189A
(ru)
|
2014-11-14 |
2020-03-11 |
Вояджер Терапьютикс, Инк. |
Композиции и способы лечения бокового амиотрофического склероза (als)
|
|
EP3230441A4
(en)
|
2014-12-12 |
2018-10-03 |
Voyager Therapeutics, Inc. |
Compositions and methods for the production of scaav
|
|
EP3889260A1
(en)
|
2014-12-12 |
2021-10-06 |
The Broad Institute, Inc. |
Protected guide rnas (pgrnas)
|
|
CA2970370A1
(en)
|
2014-12-24 |
2016-06-30 |
Massachusetts Institute Of Technology |
Crispr having or associated with destabilization domains
|
|
US10584321B2
(en)
*
|
2015-02-13 |
2020-03-10 |
University Of Massachusetts |
Compositions and methods for transient delivery of nucleases
|
|
WO2016133917A1
(en)
|
2015-02-16 |
2016-08-25 |
University Of Florida Research Foundation |
Raav vector compositions, methods for targeting vascular endothelial cells and use in treatment of type i diabetes
|
|
CN108347932B
(zh)
*
|
2015-02-20 |
2022-09-13 |
衣阿华大学研究基金会 |
用于治疗遗传性眼病的方法和组合物
|
|
CN114480502A
(zh)
*
|
2015-03-02 |
2022-05-13 |
阿德夫拉姆生物技术股份有限公司 |
用于将多核苷酸玻璃体内递送到视网膜视锥的组合物和方法
|
|
WO2016154344A1
(en)
*
|
2015-03-24 |
2016-09-29 |
The Regents Of The University Of California |
Adeno-associated virus variants and methods of use thereof
|
|
US10081659B2
(en)
|
2015-04-06 |
2018-09-25 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
Adeno-associated vectors for enhanced transduction and reduced immunogenicity
|
|
EP4019975A1
(en)
|
2015-04-24 |
2022-06-29 |
Editas Medicine, Inc. |
Evaluation of cas9 molecule/guide rna molecule complexes
|
|
US20180140626A1
(en)
*
|
2015-05-14 |
2018-05-24 |
Joslin Diabetes Center, Inc. |
Retinol-binding protein 3 (rbp3) as a protective factor in non-diabetic retinal degeneration
|
|
WO2016205759A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
|
|
MX392008B
(es)
|
2015-06-18 |
2025-03-21 |
Broad Inst Inc |
Mutaciones de la enzima crispr que reducen los efectos fuera del blanco
|
|
WO2017093566A1
(en)
*
|
2015-12-04 |
2017-06-08 |
Universite Pierre Et Marie Curie (Paris 6) |
Promoters and uses thereof
|
|
DK3387137T3
(da)
*
|
2015-12-11 |
2021-05-03 |
California Inst Of Techn |
Målretningspeptider til styring af adeno-associerede virusser (aav`er)
|
|
WO2017099838A1
(en)
|
2015-12-11 |
2017-06-15 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Gene therapy for combined methylmalonic acidemia/aciduria and hyperhomocysteinemia/homocystinuria, cobalamin c type, and deficiency of mmachc
|
|
GB2545763A
(en)
|
2015-12-23 |
2017-06-28 |
Adverum Biotechnologies Inc |
Mutant viral capsid libraries and related systems and methods
|
|
WO2017136500A1
(en)
|
2016-02-03 |
2017-08-10 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating mucopolysaccharidosis type i
|
|
WO2017165862A1
(en)
|
2016-03-25 |
2017-09-28 |
Editas Medicine, Inc. |
Systems and methods for treating alpha 1-antitrypsin (a1at) deficiency
|
|
IL322403A
(en)
|
2016-04-15 |
2025-09-01 |
Univ Pennsylvania |
Preparations for the treatment of wet age-related macular degeneration
|
|
AU2017257169B2
(en)
|
2016-04-29 |
2021-07-08 |
Adverum Biotechnologies, Inc. |
Evasion of neutralizing antibodies by a recombinant adeno-associated virus
|
|
AU2017256910B2
(en)
|
2016-04-29 |
2022-04-07 |
Centre National De La Recherche Scientifique |
Optogenetic visual restoration using Chrimson
|
|
EP3448874A4
(en)
|
2016-04-29 |
2020-04-22 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
US11299751B2
(en)
|
2016-04-29 |
2022-04-12 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
|
US11866462B2
(en)
|
2016-05-04 |
2024-01-09 |
Oregon Health & Science University |
Recombinant adeno-associated viral vectors
|
|
CN116333057A
(zh)
|
2016-05-13 |
2023-06-27 |
4D分子治疗有限公司 |
腺相关病毒变体衣壳和其使用方法
|
|
BR112018073472A2
(pt)
|
2016-05-18 |
2019-08-27 |
Voyager Therapeutics, Inc. |
composições e métodos de tratamento da doença de huntington
|
|
AU2017267665C1
(en)
|
2016-05-18 |
2023-10-05 |
Voyager Therapeutics, Inc. |
Modulatory polynucleotides
|
|
MA44546B1
(fr)
*
|
2016-06-15 |
2021-03-31 |
Univ California |
Virus adéno-associés variants et procédés d'utilisation
|
|
EP4083203B1
(en)
*
|
2016-06-16 |
2024-08-07 |
Adverum Biotechnologies, Inc. |
Compositions and methods for reducing ocular neovascularization
|
|
HUE051953T2
(hu)
|
2016-06-16 |
2021-04-28 |
Adverum Biotechnologies Inc |
Idõskori makula degeneráció kezelése AAV2 variáns és aflibercept alkalmazásával
|
|
CA3029833A1
(en)
*
|
2016-07-29 |
2018-02-01 |
The Regents Of The University Of California |
Adeno-associated virus virions with variant capsid and methods of use thereof
|
|
CA3032822A1
(en)
|
2016-08-02 |
2018-02-08 |
Editas Medicine, Inc. |
Compositions and methods for treating cep290 associated disease
|
|
US11041004B2
(en)
|
2016-08-29 |
2021-06-22 |
Wayne State University |
Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof
|
|
WO2018044933A1
(en)
|
2016-08-30 |
2018-03-08 |
The Regents Of The University Of California |
Methods for biomedical targeting and delivery and devices and systems for practicing the same
|
|
AU2017345470B2
(en)
|
2016-10-19 |
2023-08-03 |
Adverum Biotechnologies, Inc. |
Modified AAV capsids and uses thereof
|
|
WO2018106369A2
(en)
*
|
2016-11-06 |
2018-06-14 |
Nanoscope Technologies Llc |
Optogenetic modulation by multi-characteristic opsins for vision restoration and other applications thereof
|
|
US11236360B2
(en)
|
2016-12-09 |
2022-02-01 |
Regents Of The University Of Minnesota |
Adeno-associated viruses engineered for selectable tropism
|
|
KR20250022877A
(ko)
|
2017-01-31 |
2025-02-17 |
리젠엑스바이오 인크. |
완전히-인간 글리코실화된 인간 알파-l-이두로니다아제(idua)를 이용한 뮤코다당증 1형의 치료
|
|
EP3589277A4
(en)
*
|
2017-02-28 |
2020-08-26 |
Adverum Biotechnologies, Inc. |
MODIFIED AVA CAPSIDES AND USE OF THESE LATEST
|
|
WO2018170184A1
(en)
|
2017-03-14 |
2018-09-20 |
Editas Medicine, Inc. |
Systems and methods for the treatment of hemoglobinopathies
|
|
WO2018170473A1
(en)
|
2017-03-17 |
2018-09-20 |
Adverum Biotechnologies, Inc. |
Compositions and methods for enhanced gene expression
|
|
WO2018189244A1
(en)
*
|
2017-04-11 |
2018-10-18 |
Ruprecht-Karls-Universität Heidelberg |
Adeno-associated virus library
|
|
WO2018191666A1
(en)
|
2017-04-14 |
2018-10-18 |
Regenxbio Inc. |
Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2 sulfatase (ids) produced by human neural or glial cells
|
|
CA3061652A1
(en)
|
2017-05-05 |
2018-11-08 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (als)
|
|
CN111108198A
(zh)
|
2017-05-05 |
2020-05-05 |
沃雅戈治疗公司 |
治疗亨廷顿病的组合物和方法
|
|
WO2018209158A2
(en)
|
2017-05-10 |
2018-11-15 |
Editas Medicine, Inc. |
Crispr/rna-guided nuclease systems and methods
|
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
|
BR112019019015A2
(pt)
*
|
2017-06-30 |
2020-04-14 |
Univ California |
vírions de vírus adeno-associado com capsídeos variantes e seus métodos de uso
|
|
AU2018298133A1
(en)
|
2017-07-06 |
2020-01-23 |
The Trustees Of The University Of Pennsylvania |
AAV9-mediated gene therapy for treating mucopolysaccharidosis type I
|
|
CN111132626B
(zh)
|
2017-07-17 |
2024-01-30 |
沃雅戈治疗公司 |
轨迹阵列引导系统
|
|
EP3676373A4
(en)
|
2017-08-28 |
2021-06-09 |
The Regents of The University of California |
Adeno-associated virus capsid variants and methods of use thereof
|
|
BR112020005436B1
(pt)
*
|
2017-09-20 |
2022-08-02 |
4D Molecular Therapeutics Inc |
Proteína do capsídeo de variante do vírus adenoassociado, virion do aav recombinante (raav) infeccioso, composições, composições farmacêuticas e usos de virion de raav ou de composições farmacêuticas
|
|
AU2018338728B2
(en)
|
2017-09-29 |
2025-01-02 |
Centre National De La Recherche Scientifique (Cnrs) |
Rescue of central and peripheral neurological phenotype of Friedreich's Ataxia by intravenous delivery
|
|
US20200237799A1
(en)
|
2017-10-16 |
2020-07-30 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (als)
|
|
EP3697896A1
(en)
*
|
2017-10-16 |
2020-08-26 |
Vigeneron GmbH |
Aav vectors
|
|
CN111479924B
(zh)
|
2017-10-16 |
2024-06-14 |
沃雅戈治疗公司 |
肌萎缩性侧索硬化症(als)的治疗
|
|
CA3079565A1
(en)
|
2017-10-18 |
2019-04-25 |
Regenxbio Inc. |
Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified vegf-trap
|
|
CN111727201A
(zh)
|
2017-10-18 |
2020-09-29 |
再生生物股份有限公司 |
完全人源翻译后修饰的抗体治疗剂
|
|
US11723988B2
(en)
|
2017-10-20 |
2023-08-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of expressing a polynucleotide of interest in the cone photoreceptors of a subject comprising the subretinal delivery of a therapeutically effective amount of a recombinant AAV9-derived vector
|
|
US11851671B2
(en)
|
2017-10-23 |
2023-12-26 |
Regents Of The University Of Minnesota |
Programmable assembly of virus composites for receptor-targeted gene delivery
|
|
FI3717636T3
(fi)
|
2017-11-27 |
2023-06-01 |
4D Molecular Therapeutics Inc |
Adenoassosioidun viruksen kapsidivariantteja ja käyttö angiogeneesin estämisessä
|
|
US10610606B2
(en)
|
2018-02-01 |
2020-04-07 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
|
|
US20190256867A1
(en)
|
2018-02-01 |
2019-08-22 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for restoring pah gene function and methods of use thereof
|
|
CN111712566A
(zh)
|
2018-02-08 |
2020-09-25 |
应用干细胞有限公司 |
用于筛选靶基因变体的方法
|
|
CN112041437A
(zh)
|
2018-02-19 |
2020-12-04 |
同源药物公司 |
用于恢复f8基因功能的腺相关病毒组合物和其使用方法
|
|
US12558434B2
(en)
|
2018-02-20 |
2026-02-24 |
The Trustees Of The University Of Pennsylvania |
Compositions for treatment of wet age-related macular degeneration
|
|
EP3765614A1
(en)
|
2018-03-14 |
2021-01-20 |
Editas Medicine, Inc. |
Systems and methods for the treatment of hemoglobinopathies
|
|
JP7425738B2
(ja)
*
|
2018-04-03 |
2024-01-31 |
ギンコ バイオワークス インコーポレイテッド |
眼組織を標的とするウイルスベクター
|
|
CA3098565A1
(en)
|
2018-04-29 |
2019-11-07 |
Claire G. ZHANG |
Scalable clarification process for recombinant aav production
|
|
US20210231560A1
(en)
|
2018-04-29 |
2021-07-29 |
Regenxbio Inc. |
Systems and methods of spectrophotometry for the determination of genome content, capsid content and full/empty ratios of adeno-associated virus particles
|
|
KR20210010491A
(ko)
*
|
2018-05-11 |
2021-01-27 |
매사추세츠 아이 앤드 이어 인퍼머리 |
아데노-연관 바이러스의 간-특이적 향성
|
|
AU2019268330A1
(en)
|
2018-05-15 |
2020-11-26 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of Parkinson's disease
|
|
US11821009B2
(en)
|
2018-05-15 |
2023-11-21 |
Cornell University |
Genetic modification of the AAV capsid resulting in altered tropism and enhanced vector delivery
|
|
KR102930150B1
(ko)
|
2018-06-14 |
2026-02-25 |
리젠엑스바이오 인크. |
재조합 aav 생성을 위한 음이온 교환 크로마토그래피
|
|
US20210254037A1
(en)
*
|
2018-06-14 |
2021-08-19 |
Avixgen Inc. |
Pharmaceutical composition comprising fusion protein of cell-penetrating peptide and rpe65 for treatment of leber's congenital amaurosis
|
|
CN120843603A
(zh)
|
2018-07-11 |
2025-10-28 |
布里格姆妇女医院 |
用于跨血脑屏障递送试剂的方法和组合物
|
|
EP3833745A1
(en)
|
2018-08-10 |
2021-06-16 |
REGENXBIO Inc. |
Scalable method for recombinant aav production
|
|
CN113966399A
(zh)
|
2018-09-26 |
2022-01-21 |
加州理工学院 |
用于靶向基因疗法的腺相关病毒组合物
|
|
EP3856762A1
(en)
|
2018-09-28 |
2021-08-04 |
Voyager Therapeutics, Inc. |
Frataxin expression constructs having engineered promoters and methods of use thereof
|
|
JP2022513318A
(ja)
|
2018-10-01 |
2022-02-07 |
ウルトラジェニックス ファーマシューティカル インコーポレイテッド |
プロピオン酸血症を処置するための遺伝子治療
|
|
CN119684417A
(zh)
|
2018-10-02 |
2025-03-25 |
沃雅戈治疗公司 |
重新定向aav衣壳的嗜性
|
|
CN112912518A
(zh)
|
2018-10-15 |
2021-06-04 |
再生生物股份有限公司 |
用于测量复制缺陷型病毒载体和病毒的感染性的方法
|
|
MX2021006646A
(es)
*
|
2018-12-05 |
2021-12-10 |
Abeona Therapeutics Inc |
Vector viral adenoasociado recombinante para el suministro de genes.
|
|
US20200193156A1
(en)
|
2018-12-12 |
2020-06-18 |
Tesseract Health, Inc. |
Biometric identification techniques
|
|
US20220096658A1
(en)
*
|
2018-12-21 |
2022-03-31 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Svcs. |
Adeno-associated viruses and their uses for inner ear therapy
|
|
CN110437317B
(zh)
*
|
2019-01-30 |
2023-05-02 |
上海科技大学 |
具有变异衣壳蛋白的腺相关病毒及其用途
|
|
CN113728108A
(zh)
|
2019-02-15 |
2021-11-30 |
桑格摩生物治疗股份有限公司 |
用于生产重组aav的组合物和方法
|
|
US20220154211A1
(en)
|
2019-02-25 |
2022-05-19 |
Novartis Ag |
Compositions and methods to treat bietti crystalline dystrophy
|
|
BR112021016501A2
(pt)
|
2019-02-25 |
2021-10-26 |
Novartis Ag |
Composições e métodos para tratar distrofia cristalina de bietti
|
|
WO2020176747A1
(en)
|
2019-02-28 |
2020-09-03 |
Regeneron Pharmaceuticals, Inc. |
Adeno-associated virus vectors for the delivery of therapeutics
|
|
CN111621502B
(zh)
*
|
2019-02-28 |
2023-05-02 |
武汉纽福斯生物科技有限公司 |
视网膜劈裂蛋白的编码序列、其表达载体构建及其应用
|
|
AU2020231505A1
(en)
|
2019-03-04 |
2021-08-19 |
Adverum Biotechnologies, Inc. |
Sequential intravitreal administration of AAV gene therapy to contralateral eyes
|
|
EP3715358A1
(en)
*
|
2019-03-28 |
2020-09-30 |
Universität zu Köln |
Mutated adeno-associated virus capsid proteins, aav particle comprising the same and liver directed aav vector gene therapy
|
|
SG11202110607WA
(en)
|
2019-04-01 |
2021-10-28 |
Tenaya Therapeutics Inc |
Adeno-associated virus with engineered capsid
|
|
EP3946467A1
(en)
|
2019-04-03 |
2022-02-09 |
REGENXBIO Inc. |
Gene therapy for eye pathologies
|
|
TW202102526A
(zh)
*
|
2019-04-04 |
2021-01-16 |
美商銳進科斯生物股份有限公司 |
重組腺相關病毒及其用途
|
|
DK3953483T3
(da)
|
2019-04-11 |
2023-12-18 |
Regenxbio Inc |
Fremgangsmåder til størrelseskromatografi til karakterisering af sammensætninger af rekombinant adeno-associeret virus
|
|
JP7630443B2
(ja)
|
2019-04-19 |
2025-02-17 |
レジェンクスバイオ インコーポレーテッド |
アデノ随伴ウイルスベクター製剤及び方法
|
|
WO2020219868A1
(en)
|
2019-04-24 |
2020-10-29 |
Regenxbio Inc. |
Fully-human post-translationally modified antibody therapeutics
|
|
AU2020263757B2
(en)
|
2019-04-24 |
2025-08-28 |
Takara Bio Inc. |
AAV mutant having brain-targeting property
|
|
TWI862583B
(zh)
*
|
2019-04-26 |
2024-11-21 |
美商愛德維仁生物科技公司 |
用於玻璃體內遞送之變異體aav蛋白殼
|
|
JP2022530845A
(ja)
*
|
2019-04-27 |
2022-07-04 |
オクジェン アイエヌシー． |
眼疾患に対するａｄｅｎｏ随伴ウイルス連ウイルスベクター媒介遺伝子治療
|
|
US11737665B2
(en)
|
2019-06-21 |
2023-08-29 |
Tesseract Health, Inc. |
Multi-modal eye imaging with shared optical path
|
|
MX2021016014A
(es)
|
2019-06-27 |
2022-04-06 |
Univ Florida |
Mejora de la transducción mediada por aav en los tejidos oculares con ácido hialurónico.
|
|
US20220251567A1
(en)
|
2019-07-10 |
2022-08-11 |
Inserm (Institut National De La Santè Et De La Recherche Médicale) |
Methods for the treatment of epilepsy
|
|
JP7654626B2
(ja)
*
|
2019-07-11 |
2025-04-01 |
サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィック |
化学修飾型アデノ随伴ウイルス
|
|
US10653731B1
(en)
|
2019-07-15 |
2020-05-19 |
Vigene Biosciences Inc. |
Recombinantly-modified adeno-associated virus (rAAV) having improved packaging efficiency
|
|
US10557149B1
(en)
|
2019-07-15 |
2020-02-11 |
Vigene Biosciences, Inc. |
Recombinantly-modified adeno-associated virus helper vectors and their use to improve the packaging efficiency of recombinantly-modified adeno-associated virus
|
|
US10801042B1
(en)
|
2019-07-15 |
2020-10-13 |
Vigene Biosciences, Inc. |
Use of ion concentrations to increase the packaging efficiency of recombinant adeno-associated virus
|
|
US20230042103A1
(en)
|
2019-07-26 |
2023-02-09 |
Regenxbio Inc. |
Engineered nucleic acid regulatory element and methods of uses thereof
|
|
RU2751592C2
(ru)
|
2019-08-22 |
2021-07-15 |
Общество С Ограниченной Ответственностью "Анабион" |
Выделенный модифицированный белок VP1 капсида аденоассоциированного вируса 5 серотипа (AAV5), капсид и вектор на его основе
|
|
CN114502197A
(zh)
|
2019-08-26 |
2022-05-13 |
再生生物股份有限公司 |
用全人经翻译后修饰的抗VEGF Fab治疗糖尿病性视网膜病变
|
|
CN114667349A
(zh)
|
2019-09-09 |
2022-06-24 |
马萨诸塞眼科耳科诊所 |
用于调节腺相关病毒(aav)和aav受体(aavr)之间的相互作用以改变aav生物分布的方法和组合物
|
|
CN114375195A
(zh)
|
2019-09-11 |
2022-04-19 |
阿德夫拉姆生物技术股份有限公司 |
使用编码阿柏西普的aav2变体治疗眼新血管疾病的方法
|
|
AU2020347276A1
(en)
*
|
2019-09-12 |
2022-03-17 |
Massachusetts Institute Of Technology |
Engineered adeno-associated virus capsids
|
|
GB201913974D0
(en)
|
2019-09-27 |
2019-11-13 |
King S College London |
Vector
|
|
WO2021067598A1
(en)
|
2019-10-04 |
2021-04-08 |
Ultragenyx Pharmaceutical Inc. |
Methods for improved therapeutic use of recombinant aav
|
|
US20240108669A1
(en)
|
2019-10-07 |
2024-04-04 |
Regenxbio Inc. |
Adeno-associated virus vector pharmaceutical composition and methods
|
|
EP4045664A1
(en)
*
|
2019-10-16 |
2022-08-24 |
Wuxi Apptec (Shanghai) Co., Ltd. |
A novel aav variant
|
|
AU2020368539A1
(en)
|
2019-10-16 |
2022-04-28 |
Massachusetts Institute Of Technology |
Engineered muscle targeting compositions
|
|
US12509705B2
(en)
*
|
2019-10-31 |
2025-12-30 |
Universität Bern |
AAV vector variants for ocular gene delivery
|
|
AU2020379046B2
(en)
*
|
2019-11-08 |
2025-03-13 |
Regeneron Pharmaceuticals, Inc. |
CRISPR and AAV strategies for X-linked juvenile retinoschisis therapy
|
|
US20230016983A1
(en)
|
2019-11-19 |
2023-01-19 |
lNSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) |
Antisense oligonucleotides and thier use for the treatment of cancer
|
|
WO2021108530A1
(en)
*
|
2019-11-26 |
2021-06-03 |
University Of Massachusetts |
Recombinant adeno-associated virus for delivery of kh902 (conbercept) and uses thereof
|
|
EP4065596A2
(en)
|
2019-11-28 |
2022-10-05 |
RegenxBio Inc. |
Microdystrophin gene therapy constructs and uses thereof
|
|
CN115279400A
(zh)
*
|
2020-01-10 |
2022-11-01 |
布里格姆妇女医院 |
用于跨血脑屏障递送免疫治疗剂以治疗脑癌的方法和组合物
|
|
TW202140791A
(zh)
|
2020-01-13 |
2021-11-01 |
美商霍蒙拉奇醫藥公司 |
治療苯酮尿症之方法
|
|
BR112022014563A2
(pt)
|
2020-01-22 |
2022-09-13 |
Regenxbio Inc |
Método para tratamento de um sujeito humano diagnosticado com mucopolissacaridose i (mps i)
|
|
EP4097238A1
(en)
|
2020-01-29 |
2022-12-07 |
REGENXBIO Inc. |
Treatment of mucopolysaccharidosis iva
|
|
EP4096631A1
(en)
|
2020-01-29 |
2022-12-07 |
RegenxBio Inc. |
Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids) produced by human neural or glial cells
|
|
EP4103724A1
(en)
|
2020-02-14 |
2022-12-21 |
Ultragenyx Pharmaceutical Inc. |
Gene therapy for treating cdkl5 deficiency disorder
|
|
US20230235353A1
(en)
|
2020-03-19 |
2023-07-27 |
Ultragenyx Pharmaceutical Inc. |
Compositions and methods for reducing reverse packaging of cap and rep sequences in recombinant aav
|
|
WO2021202532A1
(en)
|
2020-03-31 |
2021-10-07 |
Ultragenyx Pharmaceutical Inc. |
Gene therapy for treating propionic acidemia
|
|
US20230159609A1
(en)
*
|
2020-04-10 |
2023-05-25 |
Sorbonne Université |
G-protein-gated-k+ channel-mediated enhancements in light sensitivity in rod-cone dystrophy (rcd)
|
|
BR112022021134A2
(pt)
|
2020-04-20 |
2023-02-14 |
Tenaya Therapeutics Inc |
Vírus adeno-associado com capsídeo projetado
|
|
US20230190956A1
(en)
|
2020-04-24 |
2023-06-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for preventing induction of immune responses to the transduced cells expressing a transgene product after ocular gene therapy
|
|
KR20230026986A
(ko)
|
2020-04-27 |
2023-02-27 |
4디 몰레큘러 테라퓨틱스 아이엔씨. |
코돈 최적화된 gla 유전자 및 이의 용도
|
|
IL298001A
(en)
|
2020-05-13 |
2023-01-01 |
Voyager Therapeutics Inc |
Redirecting tropism of adeno-associated virus capsids
|
|
TW202208632A
(zh)
|
2020-05-27 |
2022-03-01 |
美商同源醫藥公司 |
用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法
|
|
CA3179597A1
(en)
|
2020-05-29 |
2021-12-02 |
John G. Flannery |
Adeno-associated virus virions with variant capsids and methods of use thereof
|
|
WO2022011262A1
(en)
|
2020-07-10 |
2022-01-13 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for treating epilepsy
|
|
CN112226461B
(zh)
*
|
2020-08-21 |
2022-04-22 |
华侨大学 |
Cd4阳性细胞特异性基因传递载体及其应用
|
|
AU2021329527A1
(en)
*
|
2020-08-21 |
2023-03-23 |
Capsida, Inc. |
Adeno-associated virus compositions having preferred expression levels
|
|
US12129287B2
(en)
|
2020-09-14 |
2024-10-29 |
President And Fellows Of Harvard College |
Recombinant adeno associated virus encoding clarin-1 and uses thereof
|
|
WO2022060915A1
(en)
|
2020-09-15 |
2022-03-24 |
Regenxbio Inc. |
Vectorized lanadelumab and administration thereof
|
|
EP4214242A1
(en)
|
2020-09-15 |
2023-07-26 |
RegenxBio Inc. |
Vectorized antibodies for anti-viral therapy
|
|
CN113754728B
(zh)
*
|
2020-09-30 |
2022-07-12 |
广州派真生物技术有限公司 |
腺相关病毒突变体及其应用
|
|
US20240024508A1
(en)
|
2020-10-07 |
2024-01-25 |
Regenxbio Inc. |
Formulations for suprachoroidal administration such as high viscosity formulations
|
|
WO2022076750A2
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns or muscle delivery
|
|
MX2023003699A
(es)
|
2020-10-07 |
2023-04-21 |
Regenxbio Inc |
Virus adenoasociados para el suministro ocular de genoterapia.
|
|
WO2022076591A1
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Formulations for suprachoroidal administration such as formulations with aggregate formation
|
|
IL301947A
(en)
|
2020-10-07 |
2023-06-01 |
Regenxbio Inc |
Formulations for suprachoroidal administration such as gel formulations
|
|
CN115698304A
(zh)
|
2020-10-09 |
2023-02-03 |
特纳亚治疗股份有限公司 |
亲斑蛋白-2基因疗法的方法和组合物
|
|
WO2022094157A1
(en)
|
2020-10-28 |
2022-05-05 |
Regenxbio Inc. |
Vectorized anti-cgrp and anti-cgrpr antibodies and administration thereof
|
|
TW202233841A
(zh)
|
2020-10-28 |
2022-09-01 |
美商銳進科斯生物股份有限公司 |
用於眼適應症之載體化抗ＴＮＦ－α抗體
|
|
EP4236974A2
(en)
|
2020-10-29 |
2023-09-06 |
RegenxBio Inc. |
Vectorized factor xii antibodies and administration thereof
|
|
CN116457373A
(zh)
|
2020-10-29 |
2023-07-18 |
再生生物股份有限公司 |
用于眼部适应症的载体化TNF-α拮抗剂
|
|
CA3196439A1
(en)
*
|
2020-11-10 |
2022-05-19 |
Avirmax, Inc. |
Engineered viral capsids and methods of use
|
|
WO2022120022A1
(en)
|
2020-12-02 |
2022-06-09 |
Regeneron Pharmaceuticals, Inc. |
Crispr sam biosensor cell lines and methods of use thereof
|
|
AU2021401998A1
(en)
*
|
2020-12-16 |
2023-08-03 |
Children's Medical Research Institute |
Adeno-associated virus capsids and vectors
|
|
KR20230120128A
(ko)
|
2020-12-16 |
2023-08-16 |
리젠엑스바이오 인크. |
재조합 바이러스 입자의 생산 방법
|
|
TW202241943A
(zh)
|
2020-12-29 |
2022-11-01 |
美商銳進科斯生物股份有限公司 |
Tau特異性抗體基因療法組合物、方法及其用途
|
|
CA3205209A1
(en)
|
2021-01-21 |
2022-07-28 |
Regenxbio Inc. |
Improved production of recombinant polypeptides and viruses
|
|
WO2022173605A2
(en)
|
2021-02-10 |
2022-08-18 |
Regenxbio Inc. |
Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids)
|
|
CN113121651B
(zh)
*
|
2021-04-19 |
2023-11-17 |
信念医药科技(上海)有限公司 |
低中和抗体腺相关病毒衣壳蛋白
|
|
CN113121652B
(zh)
*
|
2021-04-19 |
2022-10-11 |
上海信致医药科技有限公司 |
视网膜和肌肉高亲和性腺相关病毒衣壳蛋白及相关应用
|
|
EP4326339B1
(en)
|
2021-04-20 |
2025-04-02 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Compositions and methods for treating retinal degenerative disorders
|
|
EP4329821A1
(en)
|
2021-04-26 |
2024-03-06 |
RegenxBio Inc. |
Microdystrophin gene therapy administration for treatment of dystrophinopathies
|
|
CA3215855A1
(en)
|
2021-04-27 |
2022-11-03 |
Julie Clark |
Methods of treating ocular diseases using aav2 variants encoding aflibercept
|
|
US20240218397A1
(en)
|
2021-05-04 |
2024-07-04 |
Regenxbio Inc. |
Novel aav vectors and methods and uses thereof
|
|
US20240358857A1
(en)
|
2021-05-11 |
2024-10-31 |
Regenxbio Inc. |
Treatment of duchenne muscular dystrophy and combinations thereof
|
|
JP2024520558A
(ja)
|
2021-05-26 |
2024-05-24 |
スパーリングヴィジョン |
Ｇタンパク質ゲート－ｋ＋チャネルを介した桿体－錐体ジストロフィー（ｒｃｄ）における光感受性の増強
|
|
CN117157309A
(zh)
*
|
2021-05-28 |
2023-12-01 |
上海瑞宏迪医药有限公司 |
衣壳变异的重组腺相关病毒及其应用
|
|
AU2022283898A1
(en)
*
|
2021-06-03 |
2024-01-04 |
Dyno Therapeutics, Inc. |
Capsid variants and methods of using the same
|
|
WO2023280926A1
(en)
|
2021-07-07 |
2023-01-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Synergistic combination of rdcfv2 and rdcvf2l for the treatment of tauopathies
|
|
JP2024523707A
(ja)
|
2021-07-08 |
2024-06-28 |
テナヤ セラピューティクス， インコーポレイテッド |
遺伝子治療のための最適化された発現カセット
|
|
WO2023004331A1
(en)
|
2021-07-19 |
2023-01-26 |
New York University |
Auf1 combination therapies for treatment of muscle degenerative disease
|
|
JP2024531138A
(ja)
|
2021-08-11 |
2024-08-29 |
ウルトラジェニックス ファーマシューティカル インコーポレイテッド |
筋ジストロフィーを処置するための組成物および方法
|
|
US20250154526A1
(en)
|
2021-08-20 |
2025-05-15 |
Joint Stock Company "Biocad" |
Method of obtaining a modified adeno-associated virus capsid
|
|
AR126839A1
(es)
|
2021-08-20 |
2023-11-22 |
Llc «Anabion» |
Proteína de la cápside vp1 modificada aislada del virus adeno-asociado de serotipo 9 (aav9), cápside y vector basado en esta
|
|
AR126840A1
(es)
|
2021-08-20 |
2023-11-22 |
Llc «Anabion» |
Proteína de la cápside vp1 modificada aislada del virus adeno-asociado de serotipo 5 (aav5), cápside y vector basado en esta
|
|
WO2023060113A1
(en)
|
2021-10-05 |
2023-04-13 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
|
CN118202060A
(zh)
|
2021-10-05 |
2024-06-14 |
再生生物股份有限公司 |
用于重组aav生产的组合物和方法
|
|
US20250001006A1
(en)
|
2021-10-07 |
2025-01-02 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for targeted delivery
|
|
WO2023060272A2
(en)
|
2021-10-07 |
2023-04-13 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns tropic delivery
|
|
MX2024004217A
(es)
|
2021-10-08 |
2024-06-26 |
Dyno Therapeutics Inc |
Variantes de cápside y métodos de uso de estas.
|
|
EP4163296A1
(en)
|
2021-10-11 |
2023-04-12 |
Sparingvision |
G-protein-gated-k+ channel-mediated enhancements in light sensitivity in patients with rod-cone dystrophy (rcd)
|
|
WO2023077092A1
(en)
|
2021-10-28 |
2023-05-04 |
Regenxbio Inc. |
Engineered nucleic acid regulatory elements and methods and uses thereof
|
|
WO2023081648A1
(en)
|
2021-11-02 |
2023-05-11 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
CN120187407A
(zh)
*
|
2021-12-15 |
2025-06-20 |
健达九州(北京)生物科技有限公司 |
重组aav载体及其用途
|
|
JP2025506383A
(ja)
|
2022-02-02 |
2025-03-11 |
アドヴェラム バイオテクノロジーズ， インコーポレイテッド |
アフリベルセプトをコードするａａｖ２バリアントを使用して眼内血管新生疾患を処置する方法
|
|
WO2023158990A1
(en)
|
2022-02-16 |
2023-08-24 |
Adverum Biotechnologies, Inc. |
Method of reducing cst fluctuation in neovascular amd by a recombinant adeno-associated virus
|
|
CN118715236A
(zh)
*
|
2022-02-17 |
2024-09-27 |
九天生物医药(上海)有限公司 |
具有经修饰的aav衣壳多肽的重组腺相关病毒
|
|
EP4490278A1
(en)
|
2022-03-07 |
2025-01-15 |
Ultragenyx Pharmaceutical Inc. |
Modified batch aav production systems and methods
|
|
EP4493226A1
(en)
|
2022-03-13 |
2025-01-22 |
RegenxBio Inc. |
Modified muscle-specific promoters
|
|
US20250213727A1
(en)
|
2022-03-25 |
2025-07-03 |
Regenxbio Inc. |
Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy
|
|
TW202404651A
(zh)
|
2022-04-06 |
2024-02-01 |
美商銳進科斯生物股份有限公司 |
用於脈絡膜上投與之調配物諸如形成聚集體之調配物
|
|
CA3247507A1
(en)
|
2022-04-06 |
2023-10-12 |
Regenxbio Inc. |
PHARMACEUTICAL COMPOSITION COMPRISING A RECOMMENDED ADENO-ASSOCIATED VIRUS (AAV) VECTOR WITH AN EXPRESSION CASSETTE ENCODED BY A TRANSGENE FOR SUPRACHOROID ADMINISTRATION
|
|
TW202345913A
(zh)
|
2022-04-06 |
2023-12-01 |
美商銳進科斯生物股份有限公司 |
用於脈絡膜上投與之調配物諸如凝膠調配物
|
|
EP4508062A1
(en)
|
2022-04-11 |
2025-02-19 |
Tenaya Therapeutics, Inc. |
Adeno-associated virus with engineered capsid
|
|
CN120590489A
(zh)
*
|
2022-04-12 |
2025-09-05 |
合肥星眸生物科技有限公司 |
一种融合型腺相关病毒及其应用
|
|
EP4507741A1
(en)
|
2022-04-14 |
2025-02-19 |
RegenxBio Inc. |
Gene therapy for treating an ocular disease
|
|
WO2023201277A1
(en)
|
2022-04-14 |
2023-10-19 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns tropic delivery
|
|
CN116970648A
(zh)
*
|
2022-04-24 |
2023-10-31 |
上海朗昇生物科技有限公司 |
新型aav衣壳改造株及其用途
|
|
US20250288697A1
(en)
|
2022-05-03 |
2025-09-18 |
Regenxbio Inc. |
Vectorized anti-tnf-alpha inhibitors for ocular indications
|
|
TW202400803A
(zh)
|
2022-05-03 |
2024-01-01 |
美商銳進科斯生物股份有限公司 |
載體化抗補體抗體與補體劑及其投與
|
|
AU2023285075A1
(en)
|
2022-06-07 |
2025-01-23 |
Adverum Biotechnologies, Inc. |
Melanopsin variants for vision restoration
|
|
WO2023239627A2
(en)
|
2022-06-08 |
2023-12-14 |
Regenxbio Inc. |
Methods for recombinant aav production
|
|
EP4558149A1
(en)
|
2022-07-21 |
2025-05-28 |
Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating chronic pain disorders
|
|
EP4568710A1
(en)
|
2022-08-11 |
2025-06-18 |
Institute Of Molecular And Clinical Ophthalmology Basel (Iob) |
Human cone photoreceptor optogenetic constructs
|
|
US20260055144A1
(en)
|
2022-08-24 |
2026-02-26 |
Regenxbio Inc. |
Recombinant adeno-associated viruses and uses thereof
|
|
US20260034250A1
(en)
|
2022-09-30 |
2026-02-05 |
Regenxbio Inc. |
Treatment of ocular diseases with recombinant viral vectors encoding anti-vegf fab
|
|
WO2024081746A2
(en)
|
2022-10-11 |
2024-04-18 |
Regenxbio Inc. |
Engineered nucleic acid regulatory elements and methods and uses thereof
|
|
EP4605537A1
(en)
|
2022-10-20 |
2025-08-27 |
Sparingvision |
Compositions and methods for treating retinal degenerative disorders
|
|
EP4357359A1
(en)
|
2022-10-20 |
2024-04-24 |
Sparingvision |
G-protein-gated-k+ channel-mediated enhancements in light sensitivity in rod-cone dystrophy (rcd)
|
|
CN120112547A
(zh)
|
2022-11-16 |
2025-06-06 |
瑞泽恩制药公司 |
包含膜结合il-12和蛋白酶可裂解接头的嵌合蛋白
|
|
WO2024146935A1
(en)
|
2023-01-06 |
2024-07-11 |
Institut National de la Santé et de la Recherche Médicale |
Intravenous administration of antisense oligonucleotides for the treatment of pain
|
|
CN118359687A
(zh)
*
|
2023-01-18 |
2024-07-19 |
上海朗昇生物科技有限公司 |
一种新衣壳蛋白变体以及其用途
|
|
KR20250142340A
(ko)
|
2023-02-02 |
2025-09-30 |
퀘세라 리미티드 |
재조합 아데노-부속 바이러스 벡터
|
|
TW202502803A
(zh)
|
2023-03-10 |
2025-01-16 |
美商戴諾治療公司 |
衣殼多肽及其使用方法
|
|
WO2024192281A2
(en)
|
2023-03-15 |
2024-09-19 |
Regenxbio Inc. |
Exon skipping gene therapy constructs, vectors and uses thereof
|
|
WO2024211831A1
(en)
|
2023-04-05 |
2024-10-10 |
Adverum Biotechnologies, Inc. |
Immune landscape signatures for ocular inflammation
|
|
WO2024211780A1
(en)
|
2023-04-07 |
2024-10-10 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
|
WO2024215653A1
(en)
|
2023-04-10 |
2024-10-17 |
Tenaya Therapeutics, Inc. |
Guide rnas, vectors, and virions for targeting mutations in the pln gene
|
|
WO2024215655A1
(en)
|
2023-04-10 |
2024-10-17 |
Tenaya Therapeutics, Inc. |
Cardioprotective bag3 therapies
|
|
WO2024216244A2
(en)
|
2023-04-13 |
2024-10-17 |
Regenxbio Inc. |
Targeting aav capsids, methods of manufacturing and using same
|
|
WO2024229389A1
(en)
*
|
2023-05-03 |
2024-11-07 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
TW202444917A
(zh)
*
|
2023-05-04 |
2024-11-16 |
美商航海家醫療公司 |
Ａａｖ衣殼變異體及其用途
|
|
WO2024233529A2
(en)
|
2023-05-07 |
2024-11-14 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
|
WO2024238853A1
(en)
|
2023-05-16 |
2024-11-21 |
Regenxbio Inc. |
Adeno-associated viruses for ocular delivery of gene therapy
|
|
WO2024238859A1
(en)
|
2023-05-16 |
2024-11-21 |
Regenxbio Inc. |
Vectorized c5 inhibitor agents and administration thereof
|
|
AU2024271004A1
(en)
|
2023-05-16 |
2026-01-15 |
Regenxbio Inc. |
Vectorized anti-complement antibodies and administration thereof
|
|
CN121219325A
(zh)
*
|
2023-05-23 |
2025-12-26 |
北京因诺惟康医药科技有限公司 |
一种腺相关病毒衣壳蛋白、包含其的腺相关病毒、载体及应用
|
|
WO2025008406A1
(en)
|
2023-07-04 |
2025-01-09 |
Institut National de la Santé et de la Recherche Médicale |
Antisense oligonucleotides and their use for the treatment of cancer
|
|
AU2024297654A1
(en)
|
2023-07-13 |
2026-01-22 |
Kriya Therapeutics, Inc. |
Complement pathway inhibitor fusions and methods of using the same
|
|
CN117230117A
(zh)
*
|
2023-08-04 |
2023-12-15 |
中国科学院深圳先进技术研究院 |
重组腺相关病毒包装质粒、突变体及其制备方法和应用
|
|
AU2024332181A1
(en)
|
2023-08-31 |
2026-02-12 |
Dyno Therapeutics, Inc. |
Capsid polypeptides and methods of use thereof
|
|
CN117143203B
(zh)
*
|
2023-09-06 |
2026-03-03 |
广州译码基因科技有限公司 |
可提高aav病毒全眼感染能力的衣壳蛋白突变体及其应用
|
|
WO2025075963A1
(en)
|
2023-10-02 |
2025-04-10 |
Regenxbio Inc. |
Methods and formulations for treating mucopolysaccharidosis ii-associated hearing loss with recombinant human iduronate-2-sulfatase
|
|
WO2025090962A1
(en)
|
2023-10-25 |
2025-05-01 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
|
CN117247434B
(zh)
*
|
2023-11-10 |
2024-02-02 |
上海朗昇生物科技有限公司 |
衣壳修饰型病毒载体及其制备和用途
|
|
WO2025106374A1
(en)
|
2023-11-13 |
2025-05-22 |
Juno Therapeutics, Inc. |
Aav production method
|
|
WO2025108407A2
(en)
|
2023-11-23 |
2025-05-30 |
Neuexcell Therapeutics (Suzhou) Co., Ltd. |
Gene therapy compositions and methods for treating glioma
|
|
WO2025113676A1
(en)
|
2023-11-29 |
2025-06-05 |
Neuexcell Therapeutics (Suzhou) Co., Ltd. |
Compositions and methods for treating stroke in primates
|
|
WO2025129085A1
(en)
|
2023-12-15 |
2025-06-19 |
Port Therapeutics, Inc. |
Use of thermal bioswitches in aav-based gene therapy
|
|
CN119080889B
(zh)
*
|
2024-09-18 |
2025-06-24 |
广州译码基因科技有限公司 |
提高aav对眼组织感染能力的衣壳蛋白突变体及应用
|
|
TW202545971A
(zh)
|
2024-02-08 |
2025-12-01 |
美商戴諾治療公司 |
殼體多肽及其使用方法
|
|
WO2025217214A2
(en)
|
2024-04-08 |
2025-10-16 |
Regenxbio Inc. |
Recombinant adeno-associated viruses and uses thereof
|
|
TW202548025A
(zh)
*
|
2024-04-08 |
2025-12-16 |
美商銳進科斯生物股份有限公司 |
載體化抗補體抗體與補體劑及其投與
|
|
WO2025214408A1
(en)
|
2024-04-10 |
2025-10-16 |
Skyline Therapeutics (Shanghai) Co., Ltd. |
Optogenetic modulation for vision restoration
|
|
WO2025214404A1
(en)
|
2024-04-10 |
2025-10-16 |
Skyline Therapeutics (Shanghai) Co., Ltd. |
Optogenetic modulation for vision restoration
|
|
WO2025237990A1
(en)
|
2024-05-14 |
2025-11-20 |
Institut National de la Santé et de la Recherche Médicale |
Antisense oligonucleotides and their use for the treatment of pulmonary fibrosis
|
|
WO2026006341A1
(en)
|
2024-06-24 |
2026-01-02 |
Regenxbio Inc. |
Microdystrophin gene therapy administration for treatment of dystrophinopathies
|
|
WO2026019885A1
(en)
|
2024-07-16 |
2026-01-22 |
Adverum Biotechnologies, Inc. |
Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept
|
|
CN118955654B
(zh)
*
|
2024-10-15 |
2025-05-16 |
朗信启昇(苏州)生物制药有限公司 |
具有变异衣壳的腺相关病毒病毒体及其用途
|